NEOMED announced today a new collaboration with Univalor, the Centre de recherche du centre hospitalier de l’Université de Montréal (CRCHUM), and Dr. Nicolas Noiseux for the development of an innovative therapy for the treatment of ischemic heart injury. Dr. Nicolas Noiseux and colleague Dr. Shant Der Sarkissian have identified a lead molecule and target stimulating powerful endogenous protective mechanisms that increase cell and tissue viability to hypoxic stress, reducing the impact of a heart attack.
“We are very honoured to collaborate with Dr. Noiseux, a renowned cardiac surgeon, and his expert team to address the pressing need to deliver new therapies that will reduce morbidity, mortality, and the economic and emotional burdens of ischemic heart disease,” said Philippe Walker, Chief Scientific Officer of NEOMED. “Our goal is to support medicinal chemistry, screening, and optimization efforts, and develop a molecule with optimal physicochemical properties for preclinical testing and Phase I entry.”
“Our studies have identified a lead pharmacological candidate and target as a starting point to develop a novel infarct-sparing drug, and we are delighted to partner with NEOMED in realizing this objective,” stated Dr. Noiseux. “The perspective of administering a potent adjunctive treatment to current pharmacotherapy aimed at decreasing the deleterious impact of ischemic cardiac injury represents a high-value proposition ameliorating the clinical outcome of patients suffering from a heart attack,” he concluded.
Jacques Simoneau, CEO of Univalor, added, “We are particularly pleased to contribute to the creation of this new partnership. Dr. Noiseux’s team and NEOMED bring complementary competences and skills that are essential to the development of this new treatment approach.”
ABOUT NEOMED AND THE NEOMED INSTITUTE
NEOMED is a not-for-profit organization whose mission is to foster the development of promising therapeutic approaches emerging from academia and biotechnology companies. Created in 2012, NEOMED supports the development of projects up to the stage of human proof of concept. NEOMED operates in a virtual mode using the services of the NEOMED Institute. The Institute is an open-access drug discovery hub with two high-tech research and development facilities; one in Technoparc Montréal’s Saint-Laurent Campus, specializing in small molecule therapeutics, and the other facility, NEOMED’s biologics and vaccine division, is located in Laval. NEOMED is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de l’Innovation et des Exportations du Québec, and the Networks of Centres of Excellence (NCE) of Canada. For more information, please visit our website: www.neomed.ca.
Univalor is a university technology transfer organization. Since 2001, it has been commercializing scientific findings and technological innovations emanating from some 2,600 researchers at the Université de Montréal and its affiliated health centres, Polytechnique Montréal and HEC Montréal. By creating links between the university and the business community, Univalor helps make businesses more competitive, generate revenue for research and, most importantly, enrich society. For more information: www.univalor.ca
For more information, please contact:
Mounia Azzi, PhD
Director, Scientific Affairs
Montreal, Quebec H4S 1Z9
Ariane Benoit O’Neil
514-340-3243 ext. 4242